Small-Molecule APOBEC3G DNA Cytosine Deaminase Inhibitors Based on a 4-Amino-1,2,4-triazole-3-thiol Scaffold

Synthesis and Structure-Activity Relationship Studies of HIV-1 Virion Infectivity Factor (Vif) Inhibitors that Block Viral Replication

(2012) Akbar Ali et al.   ChemMedChem

SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor

(2012) Idrees Mohammed et al.   ACS Medicinal Chemistry Letters

First-In-Class Small Molecule Inhibitors of the Single-Strand DNA Cytosine Deaminase APOBEC3G

(2011) Ming Li et al.   ACS Chemical Biology

Synthesis of some new [1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles starting from 5-nitro-2-furoic acid and evaluation of their antimicrobial activity

(2011) Sahar M.I. Badr et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1

(2011) J. F. Hultquist et al.   JOURNAL OF VIROLOGY

New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold

(2010) Lucie Maingot et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics

(2010) John S. Albin et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G

(2010) Shan Cen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis

(2010) H. A. Sadler et al.   JOURNAL OF VIROLOGY

Antiretroviral therapy and management of HIV infection

(2010) Paul A Volberding et al.   LANCET

Crystal Structure of the APOBEC3G Catalytic Domain Reveals Potential Oligomerization Interfaces

(2010) Shivender M.D. Shandilya et al.   STRUCTURE

Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?

(2009) Youcef Mehellou et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Extended Structure of the APOBEC3G Catalytic Domain Suggests a Unique Holoenzyme Model

(2009) Elena Harjes et al.   JOURNAL OF MOLECULAR BIOLOGY

Multiple ways of targeting APOBEC3–virion infectivity factor interactions for anti-HIV-1 drug development

(2009) Jessica L. Smith et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent

(2009) Edward P. Browne et al.   VIROLOGY

Synthesis, Characterization and X-ray Structures of AMTT-Type Schiff bases and two CuIComplexes (AMTT= 4-amino-5-methyl-2H-1,2,4-triazole-3(4H)-thione)

(2009) Masoumeh Tabatabaee et al.   ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE

HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC

(2009) Natasha Wood et al.   PLoS Pathogens

HIV-1 Accessory Proteins—Ensuring Viral Survival in a Hostile Environment

(2008) Michael H. Malim et al.   Cell Host & Microbe

The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction

(2008) A. J. Schumacher et al.   JOURNAL OF VIROLOGY

Small-molecule inhibition of HIV-1 Vif

(2008) Robin Nathans et al.   NATURE BIOTECHNOLOGY

Enhancing immunity to HIV through APOBEC

(2008) Reuben S Harris   NATURE BIOTECHNOLOGY

Cytidine deamination induced HIV-1 drug resistance

(2008) L. C. F. Mulder et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts

(2008) Kate N. Bishop et al.   PLoS Pathogens